Wistuba II - Search Results

1

Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES. Wistuba II, et al. Clin Cancer Res. 2013 Nov 15;19(22):6261-71. doi: 10.1158/1078-0432.CCR-13-0596. Epub 2013 Sep 18. Clin Cancer Res. 2013. PMID: 24048333 Free PMC article.

2

Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis.

Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Huang J, et al. Ann Diagn Pathol. 2001 Dec;5(6):321-9. doi: 10.1053/adpa.2001.29338. Ann Diagn Pathol. 2001. PMID: 11745069

3

Clonality of combined tumors.

Huang J, Behrens C, Wistuba II, Gazdar AF, Jagirdar J. Huang J, et al. Among authors: wistuba ii. Arch Pathol Lab Med. 2002 Apr;126(4):437-41. doi: 10.5858/2002-126-0437-COCT. Arch Pathol Lab Med. 2002. PMID: 11900568 Free article.

4

Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.

Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF. Toyooka S, et al. Among authors: wistuba ii. Clin Cancer Res. 2002 Jul;8(7):2292-7. Clin Cancer Res. 2002. PMID: 12114433

5

Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma.

Wistuba II, Behrens C, Albores-Saavedra J, Delgado R, Lopez F, Gazdar AF. Wistuba II, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3615-9. Clin Cancer Res. 2003. PMID: 14506148

6

Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.

Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L. Tang X, et al. Among authors: wistuba ii. Mol Cancer Res. 2004 Dec;2(12):685-91. Mol Cancer Res. 2004. PMID: 15634757

7

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.

Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM. Wislez M, et al. Among authors: wistuba ii. Cancer Res. 2005 Apr 15;65(8):3226-35. doi: 10.1158/0008-5472.CAN-04-4420. Cancer Res. 2005. PMID: 15833854

8

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. Tang X, et al. Among authors: wistuba ii. Cancer Res. 2005 Sep 1;65(17):7568-72. doi: 10.1158/0008-5472.CAN-05-1705. Cancer Res. 2005. PMID: 16140919

9

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. Fujimoto N, et al. Among authors: wistuba ii. Cancer Res. 2005 Dec 15;65(24):11478-85. doi: 10.1158/0008-5472.CAN-05-1977. Cancer Res. 2005. PMID: 16357156

10

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM. Wislez M, et al. Cancer Res. 2006 Apr 15;66(8):4198-207. doi: 10.1158/0008-5472.CAN-05-3842. Cancer Res. 2006. PMID: 16618742

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

714 results

Search Page